CH with a variant allele frequency (VAF) of ≥2% in the absence of cytopenia has been termed “clonal hematopoiesis of indeterminate potential” (CHIP), and most studies investigating the clinical effects of CH have focused on CHIP mutations. This evidence concerns the gene STUB1 and cyclic hematopoiesis.